Compare BELFA & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BELFA | CDNA |
|---|---|---|
| Founded | 1949 | 1998 |
| Country | United States | United States |
| Employees | 4964 | N/A |
| Industry | | Medical Specialities |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.6B |
| IPO Year | 1994 | 2007 |
| Metric | BELFA | CDNA |
|---|---|---|
| Price | $197.80 | $53.70 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $174.25 | $28.00 |
| AVG Volume (30 Days) | 81.1K | ★ 1.0M |
| Earning Date | 04-29-2026 | 04-28-2026 |
| Dividend Yield | ★ 0.10% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.13 |
| Revenue | ★ $491,611,000.00 | $48,324,000.00 |
| Revenue This Year | $9.74 | $16.01 |
| Revenue Next Year | $6.34 | $11.31 |
| P/E Ratio | $40.02 | ★ $25.48 |
| Revenue Growth | N/A | ★ 18.93 |
| 52 Week Low | $111.82 | $13.95 |
| 52 Week High | $293.51 | $55.16 |
| Indicator | BELFA | CDNA |
|---|---|---|
| Relative Strength Index (RSI) | 39.41 | 71.60 |
| Support Level | $194.67 | $45.74 |
| Resistance Level | $211.38 | N/A |
| Average True Range (ATR) | 6.94 | 2.18 |
| MACD | -0.23 | 0.02 |
| Stochastic Oscillator | 32.98 | 89.49 |
Bel Fuse Inc designs and manufactures electronic components that protect and connect electronic circuits. Its product portfolio is divided into three categories: magnetic solutions, power solutions & protection, and connectivity solutions. These products are used for the computer, networking, telecommunications, transportation and defense/aerospace, automotive, medical, and consumer electronics industries. Its geographical segments are the United States, Macao, United Kingdom, Slovakia, Germany, Switzerland, and All other foreign countries. Majority of the revenue is derived from United States.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.